Evidence map›Paper›PMID 32884268›Full record

ArticleInternational journal of nanomedicine2020

Molecular Imaging of Inflammation in a Mouse Model of Atherosclerosis Using a Zirconium-89-Labeled Probe.

Mona Ahmed, Tetyana Tegnebratt, Thuy A Tran, Li Lu, Peter Damberg, Anton Gisterå, Laura Tarnawski, Dianna Bone, Ulf Hedin, Per Eriksson and 3 more

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Nanomedicine for Diagnosis and Treatment of Atherosclerosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Mona AhmedDepartment of Molecular Medicine and Surgery, Center for Molecular Medicine, BioClinicum, Karolinska Institutet, Stockholm, SE 17176, Sweden.
Tetyana TegnebrattDepartment of Clinical Neuroscience, BioClinicum, Karolinska Institutet, Stockholm, SE 17176, Sweden.ORCID 0000-0003-4298-2295
Thuy A TranDepartment of Clinical Neuroscience, BioClinicum, Karolinska Institutet, Stockholm, SE 17176, Sweden.
Li LuDepartment of Clinical Neuroscience, BioClinicum, Karolinska Institutet, Stockholm, SE 17176, Sweden.
Peter DambergDepartment of Clinical Neuroscience, BioClinicum, Karolinska Institutet, Stockholm, SE 17176, Sweden.
Anton GisteråDepartment of Medicine Solna, Center for Molecular Medicine, BioClinicum, Karolinska Institutet, Stockholm, SE 17176, Sweden.ORCID 0000-0002-4614-8030
Laura TarnawskiDepartment of Medicine Solna, Center for Molecular Medicine, BioClinicum, Karolinska Institutet, Stockholm, SE 17176, Sweden.
Dianna BoneDepartment of Molecular Medicine and Surgery, Center for Molecular Medicine, BioClinicum, Karolinska Institutet, Stockholm, SE 17176, Sweden.
Ulf HedinDepartment of Molecular Medicine and Surgery, Center for Molecular Medicine, BioClinicum, Karolinska Institutet, Stockholm, SE 17176, Sweden.
Per ErikssonDepartment of Medicine Solna, Center for Molecular Medicine, BioClinicum, Karolinska Institutet, Stockholm, SE 17176, Sweden.
Staffan HolminDepartment of Clinical Neuroscience, BioClinicum, Karolinska Institutet, Stockholm, SE 17176, Sweden.ORCID 0000-0002-1628-1615
Björn Gustafsson *Department of Molecular Medicine and Surgery, Center for Molecular Medicine, BioClinicum, Karolinska Institutet, Stockholm, SE 17176, Sweden.ORCID 0000-0001-7031-2294
Kenneth Caidahl *Department of Molecular Medicine and Surgery, Center for Molecular Medicine, BioClinicum, Karolinska Institutet, Stockholm, SE 17176, Sweden.ORCID 0000-0002-5079-9696
Karolinska University Hospital · SEKarolinska Institutet · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBeyond clinical atherosclerosis imaging of vessel stenosis and plaque morphology, early detection of inflamed atherosclerotic lesions by molecular imaging could improve risk assessment and clinical management in high-risk patients. To identify inflamed atherosclerotic lesions by molecular imaging in vivo, we studied the specificity of our radiotracer based on maleylated (Mal) human serum albumin (HSA), which targets key features of unstable atherosclerotic lesions. MATERIALS AND

methodsMal-HSA was radiolabeled with a positron-emitting metal ion, zirconium-89 (

resultsPET/MRI, gamma counter measurements, and autoradiography showed the accumulation of

conclusion

Indexed as

RadioisotopesZirconiumAnimalsAortaAtherosclerosisAutoradiographyDisease Models, AnimalFemaleFluorodeoxyglucose F18HumansIsotope LabelingMacrophagesMagnetic Resonance ImagingMaleatesMice, Inbred C57BLMice, Knockout, ApoEFluorodeoxyglucose F18Maleatesmaleylated serum albumin, humanMolecular ProbesRadioisotopesRadiopharmaceuticalsSerum Albumin, HumanZirconiumZirconium-89atherosclerosishuman serum albuminmacrophagesmolecular imagingpositron emission tomographyzirconium

Identifiers

PMID32884268
PMCPMC7434576
OpenAlexW3048835441

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.